Helus Pharma's oral chemically modified version of psilocybin hit the key goals of a phase 3 study as an adjunctive treatment in major depressive disorder (MDD), leading analysts to suggest the drug could be “competitive to approved antipsychotics.”
The late-stage study had an intent-to-treat population of 222 patients with MDD. They either received a 16 mg dose of the candidate, dubbed HLP003, or placebo on Day 1 and then three weeks later. Remission rates were measured using the Montgomery–Åsberg Depression Rating Scale (MADRS), where patients give a score to indicate severity of depressive symptoms such as sadness, reduced appetite, suicidal thoughts and inner tension.
At six weeks, the least squares (LS) mean reduction from baseline in the MADRS total score for HLP003 was 19.5 points versus 11.9 points for placebo—a 7.6-point reduction that hit the study's primary endpoint. The trial also hit its secondary endpoint by demonstrating a 7-point placebo-adjusted reduction at 12 weeks, according to a Nov. 16 release.
MADRS reductions were seen as early as Day 2, when 39.3% of patients who received HLP003 were in remission compared to 15.5% of the placebo cohort.
In a note to investors this morning, Jefferies analysts concluded that the data were competitive to approved antipsychotics, noting that expectations going into the readout had been of a 5-6-point MADRS separation at Week 6.
HLP003 is a deuterated serotonergic agonist, also known as deuterated psilocin. Being deuterated involves swapping standard hydrogen atoms in the molecule for a heavier form of hydrogen called deuterium. This small atomic tweak keeps the drug’s effects the same while making it rapidly acting and more predictable.
The age-old hypothesis for MDD is that there is a chemical imbalance in the brain, specifically from lower levels of serotonin. Scientists and clinicians now believe that MDD affects an interconnected network of brain regions responsible for regulating mood, processing emotions, memory and cognitive control.
“We believe that [HLP]003 has the potential to set a new benchmark in the adjunctive treatment of MDD,” Helus CEO Michael Halstead told investors on a call this morning.
The company reported three treatment-related serious adverse events in the HLP003-treated arm of the study. During the call, executives disclosed that one of these events was a suicide attempt from a non-responder that occurred 55 days after the second dose. Two patients discontinued the study on Day 2 after treatment. There were no serious adverse events seen in the placebo arm, the company noted.
The psychedelics sector, in general, has seen renewed energy this year, with President Donald Trump ordering the FDA to prioritize reviews of psychedelic drugs for the treatment of mental illness. Eli Lilly acquired AtaiBeckley for $2.8 billion upfront in July, while Compass Pathways came one step closer to a potentially historic approval for its psilocybin formulation for depression after completing its rolling FDA submission today.
Although Helus was not one of the psychedelics companies to receive a voucher under the Trump administration's April announcement, a Helus spokesperson told Fierce at the time that the move “creates real momentum for companies like ours.”
"We expect this policy environment to meaningfully support our ability to drive interest in our clinical programs and advance toward regulatory submissions,” Helus added at the time.
With a separate phase 3 trial due to read out in the fourth quarter of 2027, Jefferies analysts suggested this morning that HLP003's eventual launch could benefit from the rollout of other psychedelic therapies in the meantime.